MediciNova, Inc.
NASDAQ:MNOV
1.26 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | MediciNova, Inc. |
| Symbool | MNOV |
| Munteenheid | USD |
| Prijs | 1.26 |
| Beurswaarde | 61,798,212 |
| Dividendpercentage | 0% |
| 52-weken bereik | 1.13 - 2.55 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Yuichi Iwaki M.D., Ph.D. |
| Website | https://www.medicinova.com |
An error occurred while fetching data.
Over MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)





